TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression

A novel target for BRAF-mutated colorectal tumors

Valentina Condelli, Annamaria Piscazzi, Lorenza Sisinni, Danilo Swann Matassa, Francesca Maddalena, Giacomo Lettini, Vittorio Simeon, Giuseppe Palladino, Maria Rosaria Amoroso, Stefania Trino, Franca Esposito, Matteo Landriscina

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Human BRAF-driven tumors are aggressive malignancies with poor clinical outcome and lack of sensitivity to therapies. TRAP1 is a HSP90 molecular chaperone deregulated in human tumors and responsible for specific features of cancer cells, i.e., protection from apoptosis, drug resistance, metabolic regulation, and protein quality control/ubiquitination. The hypothesis that TRAP1 plays a regulatory function on the BRAF pathway, arising from the observation that BRAF levels are decreased upon TRAP1 interference, was tested in human breast and colorectal carcinoma in vitro and in vivo. This study shows that TRAP1 is involved in the regulation of BRAF synthesis/ubiquitination, without affecting its stability. Indeed, BRAF synthesis is facilitated in a TRAP1-rich background, whereas increased ubiquitination occurs upon disruption of the TRAP1 network that correlates with decreased protein levels. Remarkably, BRAF downstream pathway is modulated by TRAP1 regulatory activity: indeed, TRAP1 silencing induces (i) ERK phosphorylation attenuation, (ii) cell-cycle inhibition with cell accumulation in G0-G1 and G2-Mtransitions, and (iii) extensive reprogramming of gene expression. Interestingly, a genome-wide profiling of TRAP1-knockdown cells identified cell growth and cell-cycle regulation as the most significant biofunctions controlled by the TRAP1 network. It is worth noting that TRAP1 regulation on BRAF is conserved in human colorectal carcinomas, with the two proteins being frequently coexpressed. Finally, the dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells. Therefore, this novel TRAP1 function represents an attractive therapeutic window to target dependency of BRAF-driven tumors on TRAP1 translational/quality control machinery.

Original languageEnglish
Pages (from-to)6693-6704
Number of pages12
JournalCancer Research
Volume74
Issue number22
DOIs
Publication statusPublished - Nov 15 2014

Fingerprint

Colorectal Neoplasms
Cell Cycle
Phosphorylation
Ubiquitination
Neoplasms
Quality Control
Proteins
Molecular Chaperones
Cytoprotection
Cytostatic Agents
Drug Resistance
Genome
Apoptosis
Breast Neoplasms
Gene Expression
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression : A novel target for BRAF-mutated colorectal tumors. / Condelli, Valentina; Piscazzi, Annamaria; Sisinni, Lorenza; Matassa, Danilo Swann; Maddalena, Francesca; Lettini, Giacomo; Simeon, Vittorio; Palladino, Giuseppe; Amoroso, Maria Rosaria; Trino, Stefania; Esposito, Franca; Landriscina, Matteo.

In: Cancer Research, Vol. 74, No. 22, 15.11.2014, p. 6693-6704.

Research output: Contribution to journalArticle

Condelli, V, Piscazzi, A, Sisinni, L, Matassa, DS, Maddalena, F, Lettini, G, Simeon, V, Palladino, G, Amoroso, MR, Trino, S, Esposito, F & Landriscina, M 2014, 'TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: A novel target for BRAF-mutated colorectal tumors', Cancer Research, vol. 74, no. 22, pp. 6693-6704. https://doi.org/10.1158/0008-5472.CAN-14-1331
Condelli, Valentina ; Piscazzi, Annamaria ; Sisinni, Lorenza ; Matassa, Danilo Swann ; Maddalena, Francesca ; Lettini, Giacomo ; Simeon, Vittorio ; Palladino, Giuseppe ; Amoroso, Maria Rosaria ; Trino, Stefania ; Esposito, Franca ; Landriscina, Matteo. / TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression : A novel target for BRAF-mutated colorectal tumors. In: Cancer Research. 2014 ; Vol. 74, No. 22. pp. 6693-6704.
@article{7634bfefe8ef4ad599eab7cc16ba65b6,
title = "TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: A novel target for BRAF-mutated colorectal tumors",
abstract = "Human BRAF-driven tumors are aggressive malignancies with poor clinical outcome and lack of sensitivity to therapies. TRAP1 is a HSP90 molecular chaperone deregulated in human tumors and responsible for specific features of cancer cells, i.e., protection from apoptosis, drug resistance, metabolic regulation, and protein quality control/ubiquitination. The hypothesis that TRAP1 plays a regulatory function on the BRAF pathway, arising from the observation that BRAF levels are decreased upon TRAP1 interference, was tested in human breast and colorectal carcinoma in vitro and in vivo. This study shows that TRAP1 is involved in the regulation of BRAF synthesis/ubiquitination, without affecting its stability. Indeed, BRAF synthesis is facilitated in a TRAP1-rich background, whereas increased ubiquitination occurs upon disruption of the TRAP1 network that correlates with decreased protein levels. Remarkably, BRAF downstream pathway is modulated by TRAP1 regulatory activity: indeed, TRAP1 silencing induces (i) ERK phosphorylation attenuation, (ii) cell-cycle inhibition with cell accumulation in G0-G1 and G2-Mtransitions, and (iii) extensive reprogramming of gene expression. Interestingly, a genome-wide profiling of TRAP1-knockdown cells identified cell growth and cell-cycle regulation as the most significant biofunctions controlled by the TRAP1 network. It is worth noting that TRAP1 regulation on BRAF is conserved in human colorectal carcinomas, with the two proteins being frequently coexpressed. Finally, the dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells. Therefore, this novel TRAP1 function represents an attractive therapeutic window to target dependency of BRAF-driven tumors on TRAP1 translational/quality control machinery.",
author = "Valentina Condelli and Annamaria Piscazzi and Lorenza Sisinni and Matassa, {Danilo Swann} and Francesca Maddalena and Giacomo Lettini and Vittorio Simeon and Giuseppe Palladino and Amoroso, {Maria Rosaria} and Stefania Trino and Franca Esposito and Matteo Landriscina",
year = "2014",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-14-1331",
language = "English",
volume = "74",
pages = "6693--6704",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression

T2 - A novel target for BRAF-mutated colorectal tumors

AU - Condelli, Valentina

AU - Piscazzi, Annamaria

AU - Sisinni, Lorenza

AU - Matassa, Danilo Swann

AU - Maddalena, Francesca

AU - Lettini, Giacomo

AU - Simeon, Vittorio

AU - Palladino, Giuseppe

AU - Amoroso, Maria Rosaria

AU - Trino, Stefania

AU - Esposito, Franca

AU - Landriscina, Matteo

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Human BRAF-driven tumors are aggressive malignancies with poor clinical outcome and lack of sensitivity to therapies. TRAP1 is a HSP90 molecular chaperone deregulated in human tumors and responsible for specific features of cancer cells, i.e., protection from apoptosis, drug resistance, metabolic regulation, and protein quality control/ubiquitination. The hypothesis that TRAP1 plays a regulatory function on the BRAF pathway, arising from the observation that BRAF levels are decreased upon TRAP1 interference, was tested in human breast and colorectal carcinoma in vitro and in vivo. This study shows that TRAP1 is involved in the regulation of BRAF synthesis/ubiquitination, without affecting its stability. Indeed, BRAF synthesis is facilitated in a TRAP1-rich background, whereas increased ubiquitination occurs upon disruption of the TRAP1 network that correlates with decreased protein levels. Remarkably, BRAF downstream pathway is modulated by TRAP1 regulatory activity: indeed, TRAP1 silencing induces (i) ERK phosphorylation attenuation, (ii) cell-cycle inhibition with cell accumulation in G0-G1 and G2-Mtransitions, and (iii) extensive reprogramming of gene expression. Interestingly, a genome-wide profiling of TRAP1-knockdown cells identified cell growth and cell-cycle regulation as the most significant biofunctions controlled by the TRAP1 network. It is worth noting that TRAP1 regulation on BRAF is conserved in human colorectal carcinomas, with the two proteins being frequently coexpressed. Finally, the dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells. Therefore, this novel TRAP1 function represents an attractive therapeutic window to target dependency of BRAF-driven tumors on TRAP1 translational/quality control machinery.

AB - Human BRAF-driven tumors are aggressive malignancies with poor clinical outcome and lack of sensitivity to therapies. TRAP1 is a HSP90 molecular chaperone deregulated in human tumors and responsible for specific features of cancer cells, i.e., protection from apoptosis, drug resistance, metabolic regulation, and protein quality control/ubiquitination. The hypothesis that TRAP1 plays a regulatory function on the BRAF pathway, arising from the observation that BRAF levels are decreased upon TRAP1 interference, was tested in human breast and colorectal carcinoma in vitro and in vivo. This study shows that TRAP1 is involved in the regulation of BRAF synthesis/ubiquitination, without affecting its stability. Indeed, BRAF synthesis is facilitated in a TRAP1-rich background, whereas increased ubiquitination occurs upon disruption of the TRAP1 network that correlates with decreased protein levels. Remarkably, BRAF downstream pathway is modulated by TRAP1 regulatory activity: indeed, TRAP1 silencing induces (i) ERK phosphorylation attenuation, (ii) cell-cycle inhibition with cell accumulation in G0-G1 and G2-Mtransitions, and (iii) extensive reprogramming of gene expression. Interestingly, a genome-wide profiling of TRAP1-knockdown cells identified cell growth and cell-cycle regulation as the most significant biofunctions controlled by the TRAP1 network. It is worth noting that TRAP1 regulation on BRAF is conserved in human colorectal carcinomas, with the two proteins being frequently coexpressed. Finally, the dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells. Therefore, this novel TRAP1 function represents an attractive therapeutic window to target dependency of BRAF-driven tumors on TRAP1 translational/quality control machinery.

UR - http://www.scopus.com/inward/record.url?scp=84918538315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918538315&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1331

DO - 10.1158/0008-5472.CAN-14-1331

M3 - Article

VL - 74

SP - 6693

EP - 6704

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -